After Plummeting Over 30%, Are Arcturus Therapeutics Shares Still a Good Buy?
Arcturus Therapeutics' (NASDAQ: ARCT) stock saw deep losses on May 27, in part because of spillover from news about patients in Moderna's (NASDAQ: MRNA) COVID-19 vaccine trial experiencing adverse reactions. Because both companies are working on COVID-19 vaccines, bad news about one affected the other.
After these losses, biotech investors are wondering whether it's time to buy on the dip and buckle up for the long haul with Arcturus, or whether it would be more prudent to cut their losses before they deepen. Likewise, many investors may be curious about how one company's clinical trial results could affect an entirely different company's stock so acutely.
When taking a long view of the market, it's clear that Arcturus is still worth an investment. In fact, unpacking the parallels between Arcturus's and Moderna's COVID-19 vaccine efforts shows that prospective investors in the former might soon have more than one opportunity to benefit from the latter's stumbles.
Source Fool.com
